DelveInsight’s, “Presbyopia - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Presbyopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Presbyopia Understanding
Presbyopia: Overview
Presbyopia is the gradual loss of your eyes' ability to focus on nearby objects. Presbyopia is caused by a hardening of the lens of your eye, which occurs with aging. As the eye lens becomes less flexible, it can no longer change shape to focus on close-up images. As a result, these images appear out of focus. Some signs of presbyopia include holding reading materials at arm's length, blurred vision at normal reading distance and eye fatigue along with headaches when doing close work. Presbyopia is diagnosed by a basic eye exam, which includes a refraction assessment and an eye health exam. No cure exists for presbyopia. However, there are several treatments available to correct the vision. Depending on the condition and lifestyle, one can choose from corrective lenses, contact lenses, or surgery to correct the vision.

"Presbyopia - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Presbyopia pipeline landscape is provided which includes the disease overview and Presbyopia treatment guidelines. The assessment part of the report embraces, in depth Presbyopia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Presbyopia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Presbyopia R&D. The therapies under development are focused on novel approaches to treat/improve Presbyopia.

Presbyopia Emerging Drugs Chapters
This segment of the Presbyopia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Presbyopia Emerging Drugs
• CSF-1: Orasis Pharmaceuticals
CSF-1 is an eye drop being developed to improve the quality of life for people with presbyopia by providing an alternative to reading glasses and invasive surgical procedures. Delivered as a topical solution directly to the eyes, CSF-1 contains a proprietary combination of existing and well-studied ingredients with the potential to restore near vision in people with presbyopia. The drug is currently in Phase III clinical development for the treatment of Presbyopia.

• Nyxol: Ocularis Pharma
Nyxol is a preservative-free ophthalmic solution containing 0.75% phentolamine (or 1% phentolamine mesylate), a nonselective alpha adrenergic antagonist that inhibits the contraction of smooth muscle of the iris. Nyxol is currently being developed for dim light and night vision disturbances (DLD), reversal of mydriasis, and presbyopia. Nyxol is currently in Phase IIb clinical studies for the treatment of presbyopia.
Further product details are provided in the report……..

Presbyopia: Therapeutic Assessment
This segment of the report provides insights about the different Presbyopia drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Presbyopia
There are approx. 10+ key companies which are developing the therapies for Presbyopia. The companies which have their Presbyopia drug candidates in the most advanced stage, i.e. Phase III include, Orasis Pharmaceuticals.

• Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Presbyopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Presbyopia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Presbyopia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Presbyopia drugs.

Presbyopia Report Insights
• Presbyopia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Presbyopia Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Presbyopia drugs?
• How many Presbyopia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Presbyopia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Presbyopia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Presbyopia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Orasis Pharmaceuticals
• Ocularis Pharma
• Eyenovia
• Visus Therapeutics
• Allergan
• Cellix Bio

Key Products
• CSF-1
• Nyxol
• Pilocarpine micro-formulation
• VTI 001
• AGN-241622
• CLX-OPH-561